The Genetics Company has entered a distribution agreement with Funakoshi Co., Ltd.
The Genetics Company, Inc. a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer announces that it has entered a distribution agreement with Funakoshi Co., Ltd., a prime Japanese distributor of life science research reagents and instruments. Within the scope of this agreement The Genetics Company will supply Funakoshi Co., Ltd. with its innovative Alzheimer's disease diagnostic products and research tools for exclusive distribution within Japan.
The Genetics Company's Alzheimer's disease diagnostic products and research tools enable the highly specific and selective detection of variants of human beta-Amyloid, a key protein associated with the pathogenesis of Alzheimer's disease. The Company's products include a very sensitive and reliable ELISA based kit for the quantification of beta-Amyloid 40 and 42 peptides in cerebrospinal fluid of patients (CSF ELISA), a method which already has been and continues to be validated in clinical trials and which emerges as an indispensable part of the Alzheimer's disease diagnosis process in patients. A high sensitivity research version of these test kits, especially designed for the detection of beta-Amyloid 40 and 42 peptides in cell supernatants, brain lysates and other matrices, is also available for use in preclinical research. These ELISA test kits are complemented by superior quality antibodies for the detection of beta-Amyloid 40 and 42.
These products will now become available on the Japanese market for the first time through exclusive distribution by Funakoshi Co., Ltd., who are a major Japanese distributor of innovative diagnostic products and reagents and who have recently been awarded the Gold Medal for their extraordinarily well-designed website (Bio Japan Best Web Gold Medal Award).
Dr. Ryoya Funakoshi, President & CEO of Funakoshi Co., Ltd. was quoted as saying "We are delighted with this distribution agreement, The Genetics Company's outstanding ELISAs and antibodies perfectly complement our range of top quality products and will enable us to meet the high demand for beta-Amyloid-targeted Alzheimer's diagnostic and research tools in Japan". Whereas, Dr. Harald Eistetter, CEO of The Genetics Company, adding the following comments "We appreciate that Funakoshi Co., Ltd. operates as our distributor for our Alzheimer's disease diagnostics and research tools in Japan. Funakoshi have an excellent reputation in Japan and we look forward to a long and fruitful cooperation".
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
